Fig. 4: CRS profile of patients who received the 12/32-mg two-step-up priming regimen.
From: Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
CRS experienced by each of the 119 patients who received the 12/32-mg two step-up priming regimen is shown by grade after each dose received. Grade 0 denotes no CRS.
